Last 833.00 INR
Change Today +33.95 / 4.25%
Volume 1.2M
As of 6:05 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

glenmark pharmaceuticals ltd (GNP) Snapshot

Open
806.50
Previous Close
799.05
Day High
842.85
Day Low
804.00
52 Week High
03/5/15 - 842.85
52 Week Low
05/19/14 - 507.10
Market Cap
226.0B
Average Volume 10 Days
807.5K
EPS TTM
20.01
Shares Outstanding
271.3M
EX-Date
07/10/14
P/E TM
41.6x
Dividend
2.00
Dividend Yield
0.24%
Current Stock Chart for GLENMARK PHARMACEUTICALS LTD (GNP)

Related News

No related news articles were found.

glenmark pharmaceuticals ltd (GNP) Related Businessweek News

No Related Businessweek News Found

glenmark pharmaceuticals ltd (GNP) Details

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products. The company’s products include Crofelemer, an anti diarrheal drug for symptomatic relief of non-infectious diarrhoea in patients with HIV/AIDS on anti retro viral therapy; GRC 17536 for neuropathic pain and respiratory disorders; and GRC 27864, an orally bioavailable inhibitor of mPGES-1 to treat chronic inflammatory conditions, which is in Phase I trial. Its products also comprise Vatelizumab (GBR 500) that is in Phase II study for multiple sclerosis; GBR 900, which is in is Phase I trial for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor; and GBR 830, an anti-OX40 monoclonal antibody for autoimmune disorders. In addition, the company is involved in the formulations business that focuses on therapeutic areas, such as dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. It has operations in India, Latin America, Europe, the United States, and internationally. Glenmark Pharmaceuticals Limited was founded in 1977 and is headquartered in Mumbai, India.

11,000 Employees
Last Reported Date: 07/1/14
Founded in 1977

glenmark pharmaceuticals ltd (GNP) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: 57.1M
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 16.3M
Director of Corporate Affairs, Executive Dire...
Total Annual Compensation: 18.3M
Compensation as of Fiscal Year 2014.

glenmark pharmaceuticals ltd (GNP) Key Developments

Glenmark Pharmaceuticals Ltd. Presents at Nomura India Corporate Day - Boston, Mar-03-2015

Glenmark Pharmaceuticals Ltd. Presents at Nomura India Corporate Day - Boston, Mar-03-2015 . Venue: Boston Harbor Hotel, Boston, Massachusetts, United States.

Glenmark Pharmaceuticals Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2014

Glenmark Pharmaceuticals Ltd. reported earnings results for the nine months ended December 31, 2014. The company net profit for the nine months ended December 31, 2014 was INR 4.65 billion, or INR 17.12 per diluted share, compared to INR 5.02 billion, or INR 18.41 per diluted share, for the same period ended December 31, 2013. Total income from operations for the nine months ended December 31, 2014 was INR 48.69 billion, compared to INR 43.03 billion for the same period ended December 31, 2013.

Glenmark Pharmaceuticals Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2014

Glenmark Pharmaceuticals Ltd. reported consolidated earnings results for the third quarter ended December 31, 2014. For the third quarter ended December 31, 2014, consolidated revenue was at INR 17,013.07 million against INR 16,017.52 million an increase of 6.22%. The consolidated net profit was at INR 1,147.60 million for the quarter ended December 31, 2014 as compared to INR 2,143.31 million for the previous corresponding quarter. The Profits for the quarter are not comparable because of foreign exchange losses in Emerging Markets especially Russia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNP:IN 833.00 INR +33.95

GNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,530 INR -0.35
Jubilant Life Sciences Ltd 155.25 INR -1.55
Lannett Co Inc $63.09 USD +0.81
Ranbaxy Laboratories Ltd 805.50 INR +22.95
View Industry Companies
 

Industry Analysis

GNP

Industry Average

Valuation GNP Industry Range
Price/Earnings 43.1x
Price/Sales 3.4x
Price/Book 7.0x
Price/Cash Flow 28.7x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLENMARK PHARMACEUTICALS LTD, please visit www.glenmarkpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.